These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8359564)

  • 1. Proceedings of the discussion: 'Tolerability and safety of Sandostatin'.
    Popovic V; Chayvialle JA; Wass JA
    Digestion; 1993; 54 Suppl 1():104-6. PubMed ID: 8359564
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings of the discussion, "Tolerability and safety of Sandostatin".
    Wass JA; Popovic V; Chayvialle JA
    Metabolism; 1992 Sep; 41(9 Suppl 2):80-2. PubMed ID: 1518439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long term octreotide on gall stone formation and gall bladder function.
    Bigg-Wither GW; Ho KK; Grunstein RR; Sullivan CE; Doust BD
    BMJ; 1992 Jun; 304(6842):1611-2. PubMed ID: 1628089
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR.
    Moschetta A; Stolk MF; Rehfeld JF; Portincasa P; Slee PH; Koppeschaar HP; Van Erpecum KJ; Vanberge-Henegouwen GP
    Aliment Pharmacol Ther; 2001 Feb; 15(2):181-5. PubMed ID: 11148435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gallbladder function in acromegalic patients taking long-term octreotide: evidence of rebound hypermotility on cessation of treatment.
    Rhodes M; James RA; Bird M; Clayton B; Kendall-Taylor P; Lennard TW
    Scand J Gastroenterol; 1992; 27(2):115-8. PubMed ID: 1561523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gallstones during octreotide therapy.
    Dowling RH; Hussaini SH; Murphy GM; Wass JA
    Digestion; 1993; 54 Suppl 1():107-20. PubMed ID: 8103009
    [No Abstract]   [Full Text] [Related]  

  • 7. Gall stones induced by octreotide.
    Catnach SM; Wass JA; Anderson JV; Besser M; Fairclough P; Hussaini H; Dowling H
    BMJ; 1992 Aug; 305(6848):313. PubMed ID: 1392873
    [No Abstract]   [Full Text] [Related]  

  • 8. Proceedings of the workshop, "Practical approaches to the diagnosis and treatment of acromegaly".
    Liuzzi A; Sobrinho LG; Besser GM
    Metabolism; 1992 Sep; 41(9 Suppl 2):87-90. PubMed ID: 1518440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly.
    Catnach SM; Anderson JV; Fairclough PD; Trembath RC; Wilson PA; Parker E; Besser GM; Wass JA
    Gut; 1993 Feb; 34(2):270-3. PubMed ID: 8432484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones.
    Hussaini SH; Pereira SP; Veysey MJ; Kennedy C; Jenkins P; Murphy GM; Wass JA; Dowling RH
    Gut; 1996 May; 38(5):775-83. PubMed ID: 8707128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide is effective in acromegaly but often results in cholelithiasis.
    Daughaday WH
    Ann Intern Med; 1990 Feb; 112(3):159-60. PubMed ID: 2404444
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly.
    Plöckinger U; Dienemann D; Quabbe HJ
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1658-62. PubMed ID: 2229321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of gall bladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly.
    Ewins DL; Javaid A; Coskeran PB; Shah S; Butler J; Deprez PH; Miell J; Calam J; Barrett JJ; Dawson JM
    Q J Med; 1992 Apr; 83(300):295-306. PubMed ID: 1631261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of high-dose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly.
    White MC; James RA; Chatterjee S; Mother M; Hall K; Dunne MJ; Baister ER; Kendall-Taylor P
    Horm Res; 1990; 33 Suppl 1():13-8; discussion 18-9. PubMed ID: 1972690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly.
    McKnight JA; McCance DR; Crothers JG; Atkinson AB
    BMJ; 1989 Sep; 299(6699):604-5. PubMed ID: 2508821
    [No Abstract]   [Full Text] [Related]  

  • 17. [Octreotide-induced sinus bradycardia in a male patient with acromegaly].
    Lima-Martínez MM; López-Méndez G; Mangupli R
    Endocrinol Nutr; 2013 Oct; 60(8):e7-9. PubMed ID: 23415777
    [No Abstract]   [Full Text] [Related]  

  • 18. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management.
    Redfern JS; Fortuner WJ
    Am J Gastroenterol; 1995 Jul; 90(7):1042-52. PubMed ID: 7611194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gall stones and treatment with octreotide for acromegaly.
    BMJ; 1989 Nov; 299(6708):1162-3. PubMed ID: 2513036
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute liver injury and octreotide.
    González-Martín JA; Donnay S; Morillas J; Gómez-Aparicio C; Garcia-Cano J; Pérez-Vigara G; Roldán A
    Am J Gastroenterol; 1996 Nov; 91(11):2434-5. PubMed ID: 8931436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.